Biotech and Pharmaceutical
News & Jobs
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Market Summary

Company Profiles


Research Store

Biotech Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup


Rabinder Buttar, CEO of ClinTec International, Presents at the Going Global Session of the Entrepreneur MADE Conference as Expert Panellist on India Rising

9/25/2012 10:44:10 AM

25 September 2012: Rabinder Buttar, the CEO of ClinTec International, spoke at an “India Rising” panel discussion staged on 21 September 2012, a highlight event organised to coincide with the concluding day to the 2012 MADE Entrepreneur Festival that took place in Sheffield, UK.

Other key speakers at the Festival, described as “the Davos for entrepreneurs” included Kanya King MBE, the CEO and founder of MOBO, Charles Morgan Chairman of Morgan Motor Company, the R.t. Hon. Vince Cable, MP, Secretary of State for Business, Innovation and Skills, Peter Jones, CBE, Dragon and founder of the Peter Jones Enterprise Academy, Lord Bilimoria CBE, Chairman of Cobra Beer and Julie Meyer, founder of Ariadne Capital.

Core subject areas discussed during the “India Rising” themed event included the challenges and new market opportunities thrown up by the Indian market, ripe for ambitious overseas companies to both overcome and successfully penetrate, understanding how the commercial markets and the Asian business sector operates in India and comprehending the culture of Indian based companies. Moreover, the panelists covered international market comparisons between the Chinese and Indian economies, the scope and extent to which Indian companies are actively looking for trading partners in the UK and predictions on what will emerge as the most lucrative drivers for market penetration as the specific Asian market evolves and develops over the course of the next decade. The panel discussion included an open Q&A debate for the business audience comprised of MADE festival delegates present on the day.

Commenting on her inclusion on the panel, Rabinder Buttar remarked: “I was delighted to be invited to join prominent thought leaders from the fields of industry and academia and to discuss the exciting commercial opportunities that are available right now in India’s markets for increased global trade for UK based international companies. Furthermore, I was able to touch on the consequent impact of increased trade and revenues from India as a fillip to help stimulate the growth that the UK economy needs. Indeed, it was a pleasure to share my insights and experience as the CEO of an internationally focused Clinical Research Organisation that has a strong presence in India and Asia, that thoroughly understands the local commercial culture in that part of the world and that has a strategy in place to achieve further growth from Asian markets.”

About ClinTec International

ClinTec International is a global clinical research organisation, established in 1997 by Dr Rabinder Buttar, the company’s President and CEO. ClinTec International has a presence in over 40 developed and emerging countries, covering Asia, Western Europe, Central & Eastern Europe, the Middle East and Africa, Central and South Africa, Latin America and the US.

In addition to ClinTec International’s extensive expertise in oncology, the organisation has also conducted over 400 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec International’s ‘fast, flexible and focused’ approach to clinical research ensures an added advantage to the drug development process. The organisation’s range of services includes Clinical Monitoring, Project Management, Regulatory Affairs, Medical Writing, Data Management, Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.

ClinTec, winner of the 2011 Queen’s Award for Enterprise, operates in over 40 countries to provide specialist clinical research personnel and support services to its clients, which includes 11 of the top 25 pharmaceutical companies. ClinTec has grown organically since its inception in the UK in 1997, and has recently reported a 429 per cent growth rate over the 5-year period from 2006 to 2011. The company has continued to strengthen its presence in the emerging markets as well as the more traditional Western European clinical research marketplace

About the MADE Entrepreneur Festival

The Mail on Sunday: “The MADE Festival is a great opportunity for entrepreneurs from all over the country to share their ideas and inspire the next generation of business owners.” Described as "the Davos for entrepreneurs", it brings together 3,000 British businesses with 50 high profile speakers in venues across the UK City of Sheffield. MADE maintains its position as a national agenda setter through the attendance of Business Secretary Rt. Hon. Dr Vince Cable, and the Prime Minster’s Enterprise Advisor Lord Young of Graffham.

For further information please contact:

Bobby Bal, Senior Director Corporate Development, ClinTec International Headquarters: +44 (0) 141 226 1120 or

For more information about ClinTec, please visit

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 861 3838 or e-mail:

Read at